Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 2/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 10/20 | 0.58 |
| ▸ | PARP1 | P09874 | 4/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.53 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285957 | 0.82 | PARP1 (0.57) | CHEK2PARP1ALOX5EPHX2AMY1A | |
| SCHEMBL6502402 | 0.82 | RHEB (0.55) | RHEBCHEK2ALOX5EPHX2AMY1A | |
| SCHEMBL6287143 | 0.81 | ALDH1A1 (0.72) | CHEK2PARP1ALOX5EPHX2 | |
| SCHEMBL4716703 | 0.77 | MAPT (0.53) | RHEBCHEK2ALOX5EPHX2AMY1A | |
| SCHEMBL6278620 | 0.76 | PARP1 (0.49) | CHEK2PARP1ALOX5EPHX2AMY1A | |
| SCHEMBL6283094 | 0.76 | PARP1 (0.49) | CHEK2PARP1ALOX5EPHX2 | |
| SCHEMBL6283126 | 0.76 | PARP1 (0.52) | CHEK2PARP1ALOX5EPHX2AMY1A | |
| SCHEMBL21642885 | 0.75 | ALOX5 (0.56) | RHEBCHEK2ALOX5EPHX2AMY1A | |
| SCHEMBL5651925 | 0.74 | RHEB (1.00) | RHEBCHEK2PRSS12 | |
| SCHEMBL3917065 | 0.74 | CHEK2 (0.86) | CHEK2PARP1ALOX5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | claimed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1294686-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096299-A2 | INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | RHEB 3812/4885CHEK2 3624/4885PARP1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.